Renal Mechanism of Action/Splay vs. TmG - MOA
Study identifier:MB102-020
ClinicalTrials.gov identifier:NCT00726505
EudraCT identifier:N/A
CTIS identifier:N/A
Terminated/Withdrawn
Official Title
Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects with Type 2 Diabetes Mellitus
Medical condition
Diabetes, NOS
Phase
Phase 1
Healthy volunteers
Yes
Study drug
Dapagliflozin
Sex
All
Actual Enrollment
1
Study type
Interventional
Age
18 Years - 65 Years
Date
Study Start Date: 01 Jun 2009
Primary Completion Date: 01 Aug 2009
Study Completion Date: 01 Aug 2009
Study design
Allocation: Randomized
Endpoint Classification: Pharmacokinetics/dynamics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Verification:
Verified 01 Oct 2016 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
Bristol-Myers Squibb
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Group 1 Subjects with T2DM - Dapagliflozin 5 mg | Drug: Dapagliflozin Tablets, Oral, Once Daily, up to 29 days: Other Name: BMS-512148 |
| Active Comparator: Group 2 Subjects with T2DM - Dapagliflozin 20 mg | Drug: Dapagliflozin Tablets, Oral, Once Daily, up to 29 days: Other Name: BMS-512148 |
| Active Comparator: Group 3 Healthy Subjects - Dapagliflozin 20 mg | Drug: Dapagliflozin Tablets, Oral, Once Daily, up to 29 days: Other Name: BMS-512148 |
Contacts
Investigators
Principal Investigator
Bristol-Myers Squibb
Bristol-Myers Squibb
